Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: UK Stocks Gain Amid EU Indecision On Russia Sanctions

Tue, 22nd Jul 2014 16:14

LONDON (Alliance News) - UK stocks made significant gains on Tuesday on the growing expectation that EU leaders will shy away from imposing harsh economic sanctions on Russia in response to its apparent role in the airline disaster in Ukraine.

US second-quarter earnings also have continued to remain supportive, with big names such as Coca-Cola beating expectations Tuesday, and expectations running high for technology bellwether Apple, which is still to report Tuesday as the US earnings season hits its peak.

The FTSE 100 closed up 1.0% at 6,795.34, the FTSE 250 up 1.1% at 15,650.73, and the AIM All-Share up 0.4% at 772.56.

Within European majors, the German DAX closed up 1.3%, and the CAC 40 up 1.5%.

After the European market close, stocks in the US continue to trade at, or close to, new all-time highs. The DJIA is up 0.4% at 17,123.40, the S&P 500 up 0.6% at 1,984.63, and the Nasdaq Composite up 0.8% at 4,458.77.

Pro-Russian separatists who control the area around the crash site in eastern Ukraine on Tuesday finally handed over the plane's "black-box" flight recorders to international investigators, and also allowed the passage of a train carrying the remains of those who died to outside of the rebel-controlled area.

Investors have been waiting on the sidelines in recent sessions as the growing international outrage at delays caused by the separatists to the start of a proper investigation led to an escalation of political tension between Russia and the West. Harsher economic sanctions against Russia would hurt the economies of all parties involved, particularly those within the EU, which is Russia's biggest trading partner.

EU official have been meeting in Brussels on Tuesday to discuss what measures will be imposed on Russia, but as soon as the rebels began to cooperate with investigators, commentary from officials in Brussels began to turn from harsh economic sanctions to a possible arms embargo, which is also reportedly being opposed by some nations, including Germany and France.

Some form of extra sanctions from the EU remains likely before the end of the month, but at the time of the European close, they seemed unlikely to have many teeth.

"I think the fact that EU leaders remain divided over whether to impose tougher sanctions on Russia is creating an expectation that today's meeting will be another example of what the EU does best, namely deferring any decision due to a lack of consensus," said CMC Market chief market strategist Michael Hewson.

While tensions around one of the geopolitical situations that has been weighing on market sentiment appears to be easing a little, the situation between Israel and Gaza continues to deteriorate. The death toll has continued to rise on both sides Tuesday, and at the time of the European market close, US airline Delta said it has cancelled all flights to Israel, after it was forced to divert a plane due a Hamas rocket exploding near Tel-Aviv airport.

Amongst UK stocks movers Tuesday, ARM Holdings was the stand out blue-chip gainer, closing up 5.9% after reporting a year-on-year rise in its second-quarter revenue and pretax profit. ARM's average royalty revenue per chip was 4.6 cents, down from 5.0 cents in the second quarter, as lower-cost ARM-based microcontrollers and smartcards grew faster than the high-value chips used in smartphones and tablets. Even so, the chipmaker proposed an interim dividend of 2.25 pence, up 7.1% from 2.1 pence in the previous year.

ARM supplies micro-chips for US technology giant Apple, which is due to report its second quarter results after the US closing bell.

The supermarkets dragged on the other end of the FTSE 100 Tuesday, with Tesco, Morrisons and Sainsbury's all amongst the worst performers, down 4.0%, 1.6%, and 1.4%, respectively. The supermarkets suffered a raft of broker price target cuts Tuesday, following Monday's surprise profit warning from Tesco.

Tesco itself had bucked the sector trend to close higher on Monday, on the back of positivity surrounding the appointment of Dave Lewis from Unilever as its new chief executive officer, but on Tuesday the stock wiped out all those gains and more.

Royal Mail closed down 3.4% after it warned that its UK parcel business is experiencing tougher competition than expected. The shares closed at 450.335 pence, below the closing price of 455 pence on their first day of trading in October last year. As a group, Royal Mail is performing broadly in line with expectations, as cost cutting in the letter business offset the parcel weakness in its first quarter. However, given that the hype surrounding the initial public offering was all about the potential of the parcel business, investors have reacted negatively to Tuesday's update.

Looking towards Wednesday, the UK economy and its monetary policy will be in early focus as the minutes of the July 9-10 Bank of England rate setting meeting are released at 0930 BST, followed by a speech by Governor Mark Carney from the Commonwealth Games in Glasgow at 1245 BST.

Fellow Monetary Policy Committee member Paul Fisher has also given an interview to the Independent newspaper, which will be published on its website at midnight, and in the print edition on Wednesday.

In the UK corporate calendar Wednesday, full-year results are due from FTSE 250 listed engineer Renishaw, along with second-quarter numbers from GlaxoSmithKline, and interim results from Capita and AIM-listed Staffline Group. Interim management statements will also be released by Sage Group, Carphone Warehouse, Talk Talk Telecom, and Brewin Dolphin.

By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.